ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 02/06/23

Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) fell sharply on Monday after Cantor Fitzgerald saw risks to the company's licensing deal with Johnson & Johnson ( NYSE: JNJ ), noting that the pharma giant is reportedly deprioritizing its portfolio targeted at hepatitis virus. Ac...

Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) is scheduled to announce Q1 earnings results on Monday, February 6th, after market close. The consensus EPS Estimate is $0.13 and the consensus Revenue Estimate is $174.02M (+535.1% Y/Y). Over the last 1 year, ARWR has beaten EPS es...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a poten...

Summary My portfolio, built specifically for my retirement ~20+ years from now, features growth, dividends, and risk stocks for a happy retirement. Amazing performance by Bitcoin, Tesla, and the whole market led my portfolio to double-digit gains to start the year. This is a portfol...

Summary Biotech stocks have pulled back and offer better risk to reward for investors, Direxion Daily S&P Biotech Bull 3x Shares ETF is a popular way to trade them. M&A is likely to drive prices for mid-cap and small-cap biopharma. Using a leveraged ETF like LABU is risky, e...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022. Webcast and Conference Call and Details Invest...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

Summary Pharmaceuticals and biotechnology have the best value and quality scores in the sector. Healthcare providers are close to their historical baseline in valuation and quality. Fast facts on GNOM. 10 stocks cheaper than their peers in January. This monthly article...

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

Takeda ( NYSE: TAK ) and Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) reported data from a phase 2 trial of fazirsiran (TAK-999/ARO-AAT) to treat liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD). Alpha-1 antitrypsin protein (AAT) is made in the liv...